Related Experiment Videos

Dyslipidemia in chronic kidney disease: managing a high-risk combination

Veeraish Chauhan1, Megha Vaid

  • 1Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA. vchauhan@drexelmed.edu

Postgraduate Medicine
|November 27, 2009
PubMed

Insights

Cardiovascular disease (CKD) is a major risk for patients with chronic kidney disease (CKD). Aggressive treatment of dyslipidemia is crucial for managing cardiovascular risk in CKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is the leading cause of mortality in chronic kidney disease (CKD) patients.
  • CKD is considered a CVD equivalent, necessitating aggressive management of risk factors like dyslipidemia.
  • Primary care physicians (PCPs) play a key role in managing early-stage CKD and its cardiovascular outcomes.

Purpose of the Study:

  • To discuss current guidelines for treating dyslipidemia in CKD patients.
  • To highlight challenges PCPs face in managing dyslipidemia in CKD.
  • To review existing evidence on pharmacotherapy for dyslipidemia in CKD.

Main Methods:

  • Review of current clinical guidelines for dyslipidemia management in CKD.
  • Analysis of existing studies on the safety and efficacy of lipid-lowering pharmacotherapy in CKD.
  • Discussion of ongoing research, including the Study of Heart and Renal Protection (SHARP).

Main Results:

  • Current guidelines for dyslipidemia in CKD are complex and lengthy.
  • Limited studies exist on the safety and efficacy of pharmacotherapy for dyslipidemia in CKD.
  • Ongoing studies like SHARP are expected to provide further clarity.

Conclusions:

  • Aggressive treatment of dyslipidemia is essential for CKD patients due to high CVD risk.
  • PCPs require clear, concise guidance for managing dyslipidemia in CKD.
  • Further research is needed to optimize pharmacotherapy for dyslipidemia in the CKD population.

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...